P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Erratum: Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (Blood ( 2017) 130, 5 (2709-2717) DOI: 10.1182/blood-2017-05-780049)
Journal ArticleDOI
Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial
Anne-Ségolène Cottereau,Annibale Versari,Annika Loft,Rene-Olivier Casasnovas,Monica Bellei,Romain Ricci,Stéphane Bardet,Antonio Castagnoli,Pauline Brice,John Raemaeker,Emmanuel Itti,Catherine Forpied,Tiana Raveloarivahy,Theodore Girinsky,Thierry Van der Borght,Massimo Federico,Martin Hutchings,Umberto Ricardi,Michel Meignan,Marc André +19 more
TL;DR: It has been shown that in advanced stage Hodgkin lymphoma and Primary mediastinal B cell lymphoma, total metabolic tumor volume (TMTV) or total lesion glycolysis (TLG) predicted outcome better than the bulk.
Journal ArticleDOI
Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?
Andrea Barp,Laurent Gilardin,Vadim Afanasiev,Cécile Delorme,Karine Viala,Sophie Bernard,Pauline Brice,Dimitri Psimaras,Timothée Lenglet +8 more
TL;DR: Patients with neurological complications after cancer treatment, Hôpitaux universitaires Piti e-Salpêtri ereCharles Foix et Val-de-Grâce, Paris, France.
High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma : A study using patients as their own controls
Stéphane Vignot,Nicolas Mounier,Jérôme Larghero,Pauline Brice,Laurent Quero,Cédric de Bazelaire,Marjan Ertault,Josette Brière,Isabelle Madelaine,Pharmo Christian Gisselbrecht +9 more
TL;DR: High-dose therapy and autologous stem-cell transplantation can significantly increase EFS in comparison with the duration of the LQP for indolent lymphoma patients and can change disease course.